Dr. Volker Heinemann on the Addition of SIRT to Chemotherapy for mCRC

Dr. Volker Heinemann, MD, PhD
Published: Friday, Jul 08, 2016



Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response, which is highly correlated with overall survival, was improved for patients with metastatic colorectal cancer who added selective internal radiation therapy (SIRT) to chemotherapy.

Patients with high tumor burden in the liver also showed a positive response to the addition of SIRT, with a 20% improvement in depth of response and and a 14-month improvement in progression-free survival (PFS). Heinemann said that since the liver is essential, these results are clinically relevant.


Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response, which is highly correlated with overall survival, was improved for patients with metastatic colorectal cancer who added selective internal radiation therapy (SIRT) to chemotherapy.

Patients with high tumor burden in the liver also showed a positive response to the addition of SIRT, with a 20% improvement in depth of response and and a 14-month improvement in progression-free survival (PFS). Heinemann said that since the liver is essential, these results are clinically relevant.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x